Last reviewed · How we verify
NCT06147505
XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
Phase 1, PHASE2 trial testing XS005 Injection in Tumor in 30 participants. Suspended.
2 November 2025
Quick facts
| Lead sponsor | Dushu Lake Hospital Affiliated to Soochow University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 29 October 2023 |
| Primary completion | 2 November 2025 |
| Estimated completion | 29 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- XS005 Injection — full drug profile →
Conditions studied
- Tumor — all drugs for Tumor →
Sponsor
Dushu Lake Hospital Affiliated to Soochow University
Who can join
Adults 18 to 70, any sex, with Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this clinical study is to evaluate the safety of XS005 injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Killing the killers: Natural killer cell therapy targeting glioma stem cells in high-grade glioma.
Poorva P, Mast J, Cao B, Shah MV, et al · · 2025 · cited 14× · PMID 40040281 · DOI 10.1016/j.ymthe.2025.02.043 -
Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.
Mohite P, Puri A, Dave R, Budar A, et al · · 2024 · cited 5× · PMID 38963728 · DOI 10.1097/js9.0000000000001892 -
Cell therapies against brain tumors: Clinical development and emerging prospects.
Fukuta T, Shaha S, da Silva-Candal A, Zhao Z, et al · · 2025 · PMID 41030289 · DOI 10.1002/btm2.70018
Verify or expand the search:
- PubMed search for NCT06147505
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tumor
Currently open trials in the same condition.
- NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
- NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
- NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting
Other Dushu Lake Hospital Affiliated to Soochow University trials
Trials by the same sponsor.
- NCT06018363 — Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06147505 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dushu Lake Hospital Affiliated to Soochow University
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147505.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing